Bizengri Injection
NDC 83077-100
Product Information
Bizengri (zenocutuzumab) is a BLA-approved product labeled by Merus Us, Inc.. This product is primarily utilized in pharmaceutical processing or compounding. It is supplied as a injection for intravenous administration. This product entry covers the primary NDC 83077-100 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 83077-100?
What are the uses of this product?
What are Active Ingredients of this product?
- ZENOCUTUZUMAB 20 mg/mL - an IgG1 that targets both human epidermal growth factor receptors 2 and 3
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- ZENOCUTUZUMAB (UNII: AE72RB1W1X)
- ZENOCUTUZUMAB (UNII: AE72RB1W1X) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE (UNII: X573657P6P)
- HISTIDINE (UNII: 4QD397987E)
- TREHALOSE DIHYDRATE (UNII: 7YIN7J07X4)
- POLYSORBATE 20 (UNII: 7T1F30V5YH)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2699594 - zenocutuzumab-zbco 375 MG in 18.75 ML Injection
- RxCUI: 2699594 - 18.75 ML zenocutuzumab-zbco 20 MG/ML Injection
- RxCUI: 2699594 - zenocutuzumab-zbco 375 MG per 18.75 ML Injection
- RxCUI: 2699601 - Bizengri 375 MG in 18.75 ML Injection
- RxCUI: 2699601 - 18.75 ML zenocutuzumab-zbco 20 MG/ML Injection [Bizengri]
* Please review the full disclaimer at the bottom of this page.
Patient Education
Zenocutuzumab-zbco Injection
Zenocutuzumab-zbco injection is used to treat certain types of non-small cell lung cancer (NSCLC) and pancreatic cancer. Zenocutuzumab-zbco is in a class of medications called immunotherapy. It works by stopping the growth of cancer cells.
[Learn More]
* Please review the full disclaimer at the bottom of this page.